BAVARIAN NORDIC WKN: 917165 ISIN: DK0015998017 Kürzel: 0DPB Forum: Aktien Thema: Hauptdiskussion

Warum steigt das bei so guten News nicht viel weiter an?

The company with an approved monkeypox vaccine is considering expanding production to 24 hours a day While the head of the World Health Organization has declared monkeypox a global public health emergency, the vaccine situation for the disease is much different than it was for COVID-19. Bavarian Nordic, headquartered in Denmark, has won EU approval for its monkeypox vaccine. And demand for that vaccine is spiking these days. While the company hasn’t had to turn down orders from governments seeking the vaccine so far, it’s expanding its production, and even considering a 24-hour production schedule, as the virus continues to spread. Currently, Bavarian can produce 30 million doses per year, but it’s looking to boost that capacity, though won’t give a target number. It is able to contract with other producers to make the vaccine, but says it’s trying to avoid that, and doesn’t expect governments to force it to do so, since the vaccine is not easily reproduced

Warum steigt das bei so guten News nicht viel weiter an?